U

Universitatsklinikum Erlangen | Radiation Oncology Department

Research site
(Unclaimed)
Location
Strahlenklinik, Erlangen, Bavaria, Germany
Site insights

Top conditions

Breast Cancer (3 trials)

Ovarian Cancer (2 trials)

HIV Infections (2 trials)

Stroke (2 trials)

Ischemic Stroke (2 trials)

Top treatments

AMG 479
Cx601
TAR-200
Ustekinumab
Milvexian
Methoxsalen
BMS-986165
Povorcitinib
Pembrolizumab
Guselkumab

Parent organization

This site is a part of Universitatsklinikum Erlangen

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

10 of 24
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Enrolling
Bladder Cancer
Biological: Cetrelimab
Biological: BCG Vesiculture

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast ca...

Enrolling
HER2 Positive Breast Cancer
Drug: Pertuzumab
Drug: Trastuzumab

The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and...

Enrolling
Colitis, Ulcerative
Drug: Matching Placebo
Drug: Ustekinumab Dose Based on BSA and Body Weight
Locations recently updated

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Povorcitinib
Drug: Placebo

The primary purpose of this study is to evaluate the efficacy of guselkumab compared to placebo, in combination with a 26-week glucocorticoid (GC) ta...

Active, not recruiting
Giant Cell Arteritis
Drug: Guselkumab
Drug: Placebo

A prospective, single-arm, multi-center study designed to collect real world safety and performance data of the Adagio Medical iCLAS Cryoablation Sys...

Enrolling
Paroxysmal Atrial Fibrillation
Atrial Flutter
Device: cryoablation procedure using the iCLAS Cryoablation System

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects h...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Pembrolizumab
Drug: ladiratuzumab vedotin

Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93...

Enrolling
Multiple Myeloma
Drug: CC-93269

The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease...

Active, not recruiting
Coronary Artery Disease
Coronary Artery Stenosis
Device: Percutaneous Coronary Intervention

Trial sponsors

Janssen logo

Janssen (4 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems